Vaxneuvance 2 mcg (Pneumococcal Polysaccharide Serotype 14 SUSPENSION) 2 MCG

VAXNEUVANCE 2 MCG is a pneumococcal polysaccharide vaccine designed to protect against infections caused by Streptococcus pneumoniae. This intramuscular suspension is manufactured by Merck Canada Inc. and is commonly used for preventive care.

Strength

2 MCG

Manufacturer / TM Owner

MERCK CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

VAXNEUVANCE 2 MCG is primarily used to prevent infections caused by the pneumococcal bacterium. It targets serotype 14, which is one of the strains responsible for conditions like pneumonia, meningitis, and bacteremia. This vaccine is often recommended for individuals at higher risk of pneumococcal infections, including those with weakened immune systems or chronic health conditions.

Side Effects

Common effects of VAXNEUVANCE 2 MCG may include mild soreness, redness, or swelling at the injection site. Some individuals might experience temporary fever, fatigue, or muscle aches following vaccination. These effects are generally mild and short-lived.

Precautions & Warnings

Before receiving VAXNEUVANCE 2 MCG, inform your healthcare provider about any allergies, especially to yeast or any components of the vaccine. Individuals with a history of severe allergic reactions to previous pneumococcal vaccines should exercise caution. Always follow the advice of a healthcare professional regarding vaccination.

Avoid Interactions

VAXNEUVANCE 2 MCG may interact with certain medications that affect the immune system. It is important to discuss all current medications with a healthcare provider before receiving this vaccine. Additionally, individuals with compromised immune systems may have a different response to the vaccine.

Frequently Asked Questions

VAXNEUVANCE 2 MCG is used to prevent infections caused by the pneumococcal bacterium, specifically serotype 14.

VAXNEUVANCE 2 MCG is administered as an intramuscular injection.

Common side effects may include soreness at the injection site, mild fever, fatigue, and muscle aches.

Individuals with a history of severe allergic reactions to pneumococcal vaccines or any components of VAXNEUVANCE 2 MCG should consult a healthcare provider before receiving the vaccine.

It is important to discuss all current medications with a healthcare provider to avoid potential interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.